carnitine has been researched along with Dyslipidemias in 11 studies
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carnitine deficiency is a commonly observed problem in maintenance hemodialysis (MHD) patients, which results in altered metabolism of fatty acids and subsequently development of dyslipidemia." | 9.16 | Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. ( Harandi, AA; Moghadasi, M; Mortazavi, M; Naini, AE; Sadeghi, M, 2012) |
| "L-Carnitine is a critical metabolite indispensable for the metabolism of lipids as it facilitates fatty acid transport into the mitochondrion where β-oxidation occurs." | 5.37 | The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells. ( Appanna, VD; Auger, C; Darwich, R; Lemire, J; Mailloux, R, 2011) |
| "Carnitine deficiency is a commonly observed problem in maintenance hemodialysis (MHD) patients, which results in altered metabolism of fatty acids and subsequently development of dyslipidemia." | 5.16 | Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. ( Harandi, AA; Moghadasi, M; Mortazavi, M; Naini, AE; Sadeghi, M, 2012) |
| "Carnitine is an amino acid derivative that has a key role in the regulation of fatty acid metabolism and ATP formation." | 2.43 | The use of levo-carnitine in children with renal disease: a review and a call for future studies. ( Belay, B; Esteban-Cruciani, N; Kaskel, FJ; Walsh, CA, 2006) |
| "In participants with type 2 diabetes, after Bonferroni correction and rigorous adjustment, SDNN was inversely associated with higher levels of diacyl-phosphatidylcholine (PCaa) C32:0, PCaa C34:1, acyl-alkyl-phosphatidylcholine (PCae) C36:0, SM C16:0 and SM C16:1." | 1.62 | Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes. ( Bönhof, GJ; Knebel, B; Kotzka, J; Roden, M; Straßburger, K; Strom, A; Szendroedi, J; Ziegler, D, 2021) |
| "L-Carnitine is a critical metabolite indispensable for the metabolism of lipids as it facilitates fatty acid transport into the mitochondrion where β-oxidation occurs." | 1.37 | The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells. ( Appanna, VD; Auger, C; Darwich, R; Lemire, J; Mailloux, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, Y | 1 |
| Sun, Y | 1 |
| Sun, L | 1 |
| Liu, X | 1 |
| Zeng, R | 1 |
| Lin, X | 1 |
| Li, Y | 1 |
| Ziegler, D | 1 |
| Strom, A | 1 |
| Straßburger, K | 1 |
| Knebel, B | 1 |
| Bönhof, GJ | 1 |
| Kotzka, J | 1 |
| Szendroedi, J | 1 |
| Roden, M | 1 |
| Duta-Mare, M | 1 |
| Sachdev, V | 1 |
| Leopold, C | 1 |
| Kolb, D | 1 |
| Vujic, N | 1 |
| Korbelius, M | 1 |
| Hofer, DC | 1 |
| Xia, W | 1 |
| Huber, K | 1 |
| Auer, M | 1 |
| Gottschalk, B | 1 |
| Magnes, C | 1 |
| Graier, WF | 1 |
| Prokesch, A | 1 |
| Radovic, B | 1 |
| Bogner-Strauss, JG | 1 |
| Kratky, D | 1 |
| Higashimoto, M | 1 |
| Isoyama, N | 1 |
| Ishibashi, S | 1 |
| Ogawa, N | 1 |
| Takiguchi, M | 1 |
| Suzuki, S | 1 |
| Ohnishi, Y | 1 |
| Sato, M | 1 |
| Zhou, P | 1 |
| Zhang, J | 1 |
| He, N | 1 |
| Chang, G | 1 |
| Li, J | 1 |
| Gu, Q | 1 |
| Salmanoglu, DS | 1 |
| Gurpinar, T | 1 |
| Vural, K | 1 |
| Ekerbicer, N | 1 |
| Darıverenli, E | 1 |
| Var, A | 1 |
| Lee, J | 1 |
| Choi, J | 1 |
| Scafidi, S | 1 |
| Wolfgang, MJ | 1 |
| Galvano, F | 1 |
| Li Volti, G | 1 |
| Malaguarnera, M | 2 |
| Avitabile, T | 1 |
| Antic, T | 1 |
| Vacante, M | 1 |
| Lemire, J | 1 |
| Mailloux, R | 1 |
| Darwich, R | 1 |
| Auger, C | 1 |
| Appanna, VD | 1 |
| Naini, AE | 1 |
| Sadeghi, M | 1 |
| Mortazavi, M | 1 |
| Moghadasi, M | 1 |
| Harandi, AA | 1 |
| Belay, B | 1 |
| Esteban-Cruciani, N | 1 |
| Walsh, CA | 1 |
| Kaskel, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Low-Carbohydrate or Restricted-Calories Diet on Body Weight[NCT01358890] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carnitine and Dyslipidemias
| Article | Year |
|---|---|
The use of levo-carnitine in children with renal disease: a review and a call for future studies.
Topics: Anemia; Carnitine; Child; Dyslipidemias; Humans; Kidney Diseases; Kidney Failure, Chronic; Stereoiso | 2006 |
3 trials available for carnitine and Dyslipidemias
| Article | Year |
|---|---|
Effects of gut microbiota and fatty acid metabolism on dyslipidemia following weight-loss diets in women: Results from a randomized controlled trial.
Topics: Adult; Caloric Restriction; Carnitine; Diet, Carbohydrate-Restricted; Diet, Reducing; Dyslipidemias; | 2021 |
Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus.
Topics: Apoprotein(a); Blood Glucose; Body Mass Index; Carnitine; Cholesterol, HDL; Cholesterol, LDL; Diabet | 2009 |
Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients.
Topics: Administration, Oral; Adult; Aged; Carnitine; Cholesterol; Dietary Supplements; Dyslipidemias; Femal | 2012 |
7 other studies available for carnitine and Dyslipidemias
| Article | Year |
|---|---|
Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes.
Topics: Adult; Autonomic Nervous System Diseases; Carnitine; Diabetes Mellitus, Type 1; Diabetes Mellitus, T | 2021 |
Lysosomal acid lipase regulates fatty acid channeling in brown adipose tissue to maintain thermogenesis.
Topics: Acetyl Coenzyme A; Adipocytes, Brown; Adipose Tissue, Brown; Animals; Autophagy; Body Temperature; C | 2018 |
Preventive effects of metallothionein against DNA and lipid metabolic damages in dyslipidemic mice under repeated mild stress.
Topics: Adiponectin; Animals; Carnitine; Corticosterone; Diet, High-Fat; DNA Damage; Dyslipidemias; Female; | 2013 |
[Study on the correlation between serum lipid and serum carnitine palmitoyl transferase 1A in rural adults over 40 years in Tianjin].
Topics: Adult; Carnitine; Carnitine O-Palmitoyltransferase; China; Cholesterol; Cholesterol, HDL; Dyslipidem | 2014 |
Melatonin and L-carnitin improves endothelial disfunction and oxidative stress in Type 2 diabetic rats.
Topics: Animals; Antioxidants; Carnitine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, | 2016 |
Hepatic Fatty Acid Oxidation Restrains Systemic Catabolism during Starvation.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Carnitine; Carnitine O-Palmitoyltransferase; Di | 2016 |
The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells.
Topics: Aluminum; Astrocytes; Carnitine; Cell Line, Tumor; Dyslipidemias; gamma-Butyrobetaine Dioxygenase; H | 2011 |